linjc16/ctgov huggingface dataset:
The Test-retest Effect of the d2 Test of Attention.

Study Overview
=================
Brief Summary
-----------------
The d2 test of attention has been used in studies regarding sleep deprivation due to night shifts in hospital staff, in order to determine whether sleep deprivation has an impact on performance. However, by repeating the test there appears to be a test-retest effect, as the participants improve when performing the test more than once. The aim of this study is to determine, whether the d2 test of attention has a test-retest effect.

Detailed Description
-----------------
20 surgeons and 20 surgical nurses will be included in this study. They will be asked, after thorough instruction, to perform the d2 test of attention after a designed schedule. The participants will on day 1 and 2 perform the test 3 times consecutively at intervals of 5 minutes. On day 3, 4 and 5 the test will be repeated only once. After the 5th day follows a 7-day-break. On day 13 the test will again be performed once.

Official Title
-----------------
The Test-retest Effect of the d2 Test of Attention - a Test for Concentration and Performance.

Conditions
-----------------
Cognition and Attention in Surgeons and Nurses

Intervention / Treatment
-----------------
* Other: d2 test of attention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Nurses and surgeons at the department of Surgery, Herlev hospital. Age 22-55 years. Exclusion Criteria: Known sleep disturbances and attentional deficits, previous use of the d2 test of attention, use of central stimulating drugs

Ages Eligible for Study
-----------------
Minimum Age: 22 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: d2 test of attention<br> | Other: d2 test of attention<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Test score for the d2 test of attention |  | one year |
Effectiveness of Plasma Transfusions in Critical Care Patients

Study Overview
=================
Brief Summary
-----------------
Measuring the effectiveness of plasma transfusions in critical care

Detailed Description
-----------------
Measuring the effectiveness of plasma transfusions in critical care

Official Title
-----------------
Effectiveness of Fresh Frozen Plasma in Critical Care (EPICC) Trial

Conditions
-----------------
Coagulation

Intervention / Treatment
-----------------
* Drug: Frozen Plasma


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ICU Admission INR > 1.2 Require FFP for active bleeding and/or prior to an invasive procedure Are able to provide consent or proxy consent Exclusion Criteria: Congenital or acquired coagulation factor deficiency Platelet count < 50 x 109 /L and have NOT received subsequent platelet transfusion Consumptive coagulopathy (bleeding ≥ 3 sites and ↓ plts, ↓ fib, ↑ d dimer) Uncontrolled bleeding (6 or more units of blood in the last 6 hours) Receiving therapeutic doses of heparin/heparinoid (must be off for at least 6 hours) Have received clotting factor concentrates in the previous 24 hours Are expected to require surgery in the next 48 hours Survival expected to be less than 48 hours Currently enrolled in another study with a similar outcome Previous enrollment in this study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Frozen Plasma|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the proportion of patients with a correction of the INR (Determined by the treating physician) |  |  | 
| Secondary outcomes include changes in coagulation tests (INR, aPTT and individual coagulation factor levels |  |  | 
| bleeding and complications from FFP (fluid overload, transfusion reactions). |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary outcomes include changes in coagulation tests (INR, aPTT and individual coagulation factor levels |  |  | 
| bleeding and complications from FFP (fluid overload, transfusion reactions). |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Plasma, Trauma, Critical Care
Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
A Laboratory Study to Evaluate Urine and Blood Biomarkers That Can Distinguish Between the Presence or Absence of Aggressive Prostate Cancer

Detailed Description
-----------------
The over-arching goal of this study is to evaluate if biomarkers within the blood or urine of men with localized prostate cancer can distinguish between those with indolent cancer, defined as Gleason Grade Groups 1 and 2 and those with more aggressive disease (Gleason Grade Groups 3, 4, and 5).

Official Title
-----------------
A Laboratory Study To Evaluate A Blood Biomarker That Can Distinguish Between the Presence Or Absence of Aggressive Prostate Cancer

Conditions
-----------------
Prostate Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has been diagnosed with Prostate Cancer and is planning on having a Radical Prostatectomy performed at the Global Robotics Institute. Diagnostic PSA ≤ 20 ng/mL. Pathology report from most recent positive biopsy, prior to Radical Prostatectomy, is available. Ability to read and understand the informed consent form. Patient must have signed informed consent form Exclusion Criteria: Any of the following active therapies received: radiation, chemotherapy, biologic agents, surgery, local therapies including cryotherapy or HIFU. Diagnostic PSA > 20 ng/mL or missing PSA. Patients who are unable or unwilling to provide informed consent.
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characterize the distribution of clinical/pathological factors of the samples by the Gleason Grade Group and to characterize the distribution of the signal of each biomarker by the Gleason Grade Group or combination of groups. |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Active Surveillance, Radical Prostatectomy
PINS Stimulator System for Deep Brain Stimulation to Treat Obesity

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical study is to verify the long term effecacy and safety of a bilateral deep brain stimulation (DBS) produced by Beijing PINS Medical Co., Ltd. as a treatment option for patients with obesity.

Official Title
-----------------
PINS Stimulator System for Deep Brain Stimulation to Treat Obesity

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Device: Deep Brain Stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is aged 18 to 65. Body Mass Index [BMI] >40 kg/m2. Exclusion Criteria: Medical contraindications for general anesthesia, craniotomy, or DBS surgery Evidence of neurological disorders, e.g., multiple sclerosis, Parkinson's disease and ischemic stroke, or severe brain atrophy or the presence of subdural hygromas or subdural hematomas. Participate in other clinical trial; Has a life expectancy of < 1 year. The investigator and/or enrollment review committee, would preclude participation in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Deep Brain Stimulation<br>Stimulation is on. | Device: Deep Brain Stimulation<br> <br> * Other names: PINS Stimulator System;|
| Sham Comparator: Placebo<br>Sham Stimulation: Stimulation is off. | Device: Deep Brain Stimulation<br> <br> * Other names: PINS Stimulator System;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Weight | Body weight will be recorded at every follow-up visit. | 12 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Mass Index (BMI) |  | 12 month | 
| Food Intake |  | 12 month |
Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is investigating the effect of testosterone treatment on paraoxonase level in male patients with hypogonadotrophic hypogonadism

Official Title
-----------------
Phase IV Study to Investigate the Effect of Testosterone Treatment on Paraoxonase Level in Male Patients With Hypogonadotrophic Hypogonadism

Conditions
-----------------
Hypogonadism

Intervention / Treatment
-----------------
* Drug: Sustanon


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Volunteers patients with hypogonadism Exclusion Criteria: Coronary heart disease Other pituitary/hypothalamic disorders or other non-hypogonadism diseases None was receiving vitamins, lipid-lowering drugs, or other medications known to interfere with PON1 activity, lipid profile, or gonadal function

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: testosterone replacement therapy<br> | Drug: Sustanon<br>* 250 mg/21 days<br>* Other names: no name;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| paraoxonase level after testosterone treatment |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypogonadism, paraoxonase, Hipogonadism
Gestational Diabetes Mellitus and Cardiovascular Disease: The Role of Vascular Dysfunction

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to look at whether there are differences in blood vessel function, risk for developing diabetes (high blood sugar), lipid (blood fat) levels, and levels of other blood markers between black women and white women who have or do not have gestational diabetes mellitus.

Official Title
-----------------
Gestational Diabetes Mellitus and Cardiovascular Disease: The Role of Vascular Dysfunction

Conditions
-----------------
Pregnancy, Gestational Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy women of self-identified African descent (black) and European (white) ancestry, 18-40 years of age, Body mass index < 35 kg/m2 History of regular menstrual cycles, Are currently pregnant and in third trimester of pregnancy (after 24 weeks gestational age) Have no pregnancy-associated complications to-date Are in good health free of hypertension, as well as thyroid, cardiac, or renal disease. Exclusion Criteria: History of smoking Are taking potentially vasoactive medications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Black women in the third trimester of a pregnancy complicated by gestational diabetes. | |
| 2<br>Black women in the third trimester of a normal, uncomplicated pregnancy. | |
| 3<br>White women in the third trimester of a pregnancy complicated by gestational diabetes. | |
| 4<br>White women in the third trimester of a normal, uncomplicated pregnancy. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endothelial function |  | same day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gestational diabetes mellitus, pregnancy, cardiovascular disease risk
Registry to Collect Health Information About Desmoplastic Small Round Cell Tumor

Study Overview
=================
Brief Summary
-----------------
This study is a patient registry of people with Desmoplastic Small Round Cell Tumor (DSRCT). A patient registry is a collection of health information about a group of people, and it is usually focused on a specific diagnosis or disease. The purpose of this registry is to create a database- a collection of information-or better understanding DSRCT. Researchers will use the information from this database to learn more about DSRCT and for current and future research on DSRCT.

Official Title
-----------------
Registry for Patients With Desmoplastic Small Round Cell Tumor

Conditions
-----------------
Desmoplastic Small Round Cell Tumor

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants must have a diagnosis of desmoplastic small round cell tumor Participants may be of any age as long as the appropriate consent and assent may be obtained Willing to provide historical and longitudinal clinical data Exclusion Criteria: Participant unwilling to provide consent or share historical and longitudinal clinical data
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Desmoplastic small round cell tumor (DSRCT)<br>Collect historical/longitudinal clinical, radiographic and molecular features of DSRCT patients as documented in medical records to improve knowledge about DSRCT | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Registry to Collect Health Information About Desmoplastic Small Round Cell Tumor | The aim of this study is the collection of data. | 7 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patient registry, 20-551
Effectiveness of Toothbrushing Techniques in Plaque Removal and Caries Lesion Control

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the effectiveness of cross-toothbrushing technique compared with anteroposterior and biofilm removal and control of caries lesions in first permanent molars.

Detailed Description
-----------------
220 children between 5-7 years with at least one permanent molar erupting will be selected, with a maximum score of ICDAS 3. These children will be randomly allocated into two groups according to the technique adopted. The teeth will be evaluated by ICDAS, laser fluorescence (DIAGNOdent), QLF and subtraction radiography at baseline and after 15 days, 3, 6, 9,12,18,24 months.

Official Title
-----------------
Effectiveness of Toothbrushing Techniques in Plaque Removal and Caries Lesion Control in Erupting Primary Permanent Molars - Randomized Clinical Trial Abbreviated Over 24 Months

Conditions
-----------------
Caries

Intervention / Treatment
-----------------
* Behavioral: modified toothbrush with multilevel filaments
* Behavioral: cross toothbrushing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: erupting primary permanent molar Exclusion Criteria: caries ( ICDAS 4,5 and 6), enamel defects, sealant, restoration

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: multilevel filaments toothbrush<br>Children will brush with anteroposterior toothbrushing and a modified toothbrush (multilevel filaments) | Behavioral: modified toothbrush with multilevel filaments<br>* After the allocation of patients in this group they were instructed to brush their first molars erupt with the brushing technique anteroposterior.<br>* Other names: stages, oral b;|
| Active Comparator: cross toothbrushing<br>Children will brush with cross toothbrushing. | Behavioral: cross toothbrushing<br>* Children allocated to the group multi-bristled brush will be modified compared to the results of the group cross toothbrushing technique<br>* Other names: buccal-lingual technique;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| dental caries |  | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| dental plaque | Dental plaque accumulation after short and long term analysis | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
caries, primary molars, plaque, toothbrushing
Comparison Between Two Analgesic Methods for Pain Relief Following Surgical Abortion

Study Overview
=================
Brief Summary
-----------------
To compare between the efficacy of Paracetamol IV vs. Lornoxicam IV in pain relief following surgical abortion. The medication will be given at the time of the procedure. Following the abortion, pain level will be evaluated.

Detailed Description
-----------------
Patients with medical indication for surgical abortion during first trimester will be divided to two groups. The study groups, the surgeons and the nurses will be blinded to one of the treatment arms. Pain will be evaluated at fixed intervals following the abortion. Comparison in pain levels between the study groups will be analysed.

Official Title
-----------------
Comparison Between Two Analgesic Methods for Pain Relief Following Surgical Abortion

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: Paracetamol
* Drug: lornoxicam


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective surgical abortion for first trimester pregnancy Exclusion Criteria: Chronic pelvic pain Fibromyalgia Pelvic inflammatory disease Chronic renal failure, liver disease, peptic ulcer cervical stenosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Paracetamol<br>Pain treatment, aniline analgesics | Drug: Paracetamol<br>* Pain treatment with aniline analgesics (paracetamol) at the time of the procedure<br>* Other names: Pain relief;Drug: lornoxicam<br>* Pain treatment with NSAID (lornoxicam) at the time of the procedure<br>* Other names: Pain relief;|
| Active Comparator: lornoxicam<br>Pain treatment, nonsteroidal anti-inflammatory (NSAID) | Drug: Paracetamol<br>* Pain treatment with aniline analgesics (paracetamol) at the time of the procedure<br>* Other names: Pain relief;Drug: lornoxicam<br>* Pain treatment with NSAID (lornoxicam) at the time of the procedure<br>* Other names: Pain relief;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain | Pain level will be evaluated by VAS | Two hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pain, abortion, paracetamol, lornoxicam
Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment

Study Overview
=================
Brief Summary
-----------------
Quality of Life (QoL) in Korean postmenopausal osteoporosis patients with bisphosphonate treatment

Detailed Description
-----------------
Cross-sectional quality of life survey using self-administered OPSAT-QTM questionnaire in Korean postmenopausal osteoporosis patients with bisphosphonate treatment

Official Title
-----------------
Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment

Conditions
-----------------
Osteoporosis, Postmenopausal

Intervention / Treatment
-----------------
* Other: OPSAT-Q


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Who have been diagnosed with postmenopausal osteoporosis by physician Who have received any oral bisphosphonates (weekly or monthly) at least for 2 months to provide answer of OPSAT-QTM questionnaire Who provide informed consent for study participation Exclusion Criteria: Do not understand the contents of the questionnaire

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Bisphosphonates<br>Korean postmenopausal osteoporosis patients with bisphosphonate treatment | Other: OPSAT-Q<br>* A linguistically validated Korean version of OPSAT-Q<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean of composite satisfaction score (CSS) of OPSAT-QTM |  | 0day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean of subscale satisfaction scores of OPSAT-QTM |  | oday | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bisphosphonates, OPSAT-Q